Upstaging to pT3a in Patients Undergoing Partial or Radical Nephrectomy for cT1 Renal Tumors: A Systematic Review and Meta-analysis of Outcomes and Predictive Factors

被引:35
|
作者
Veccia, Alessandro [1 ,2 ,3 ,4 ]
Falagario, Ugo [1 ,5 ]
Martini, Alberto [6 ]
Marchioni, Michele [7 ]
Antonelli, Alessandro [8 ]
Simeone, Claudio [2 ,3 ,4 ]
Cormio, Luigi [5 ]
Capitanio, Umberto [6 ]
Mir, M. Carmen [9 ]
Derweesh, Ithaar [10 ]
Van Poppel, Hendrik [11 ]
Porpiglia, Francesco [12 ]
Autorino, Riccardo [1 ]
机构
[1] VCU Hlth Syst, Div Urol, Richmond, VA USA
[2] ASST Spedali Civili Hosp, Urol Unit, Brescia, Italy
[3] Univ Brescia, Dept Med & Surg Specialties, Radiol Sci, Brescia, Italy
[4] Univ Brescia, Publ Hlth, Brescia, Italy
[5] Univ Foggia, Dept Med & Surg Sci, Urol & Renal Transplantat Unit, Foggia, Italy
[6] IRCCS Osped San Raffaele, Urol Res Inst URI, Div Expt Oncol, Unit Urol, Milan, Italy
[7] Univ G dAnnunzio, Dept Med Oral & Biotechnol Sci, Urol Unit, Chieti, Italy
[8] Univ Verona, Dept Surg Dent Pediat & Gynecol, AUOI Verona, Urol Unit, Verona, Italy
[9] Fdn Inst Valenciano Oncol, Dept Urol, Valencia, Spain
[10] Univ Calif San Diego, Dept Urol, San Diego, CA USA
[11] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Urol, Leuven, Belgium
[12] San Luigi Gonzaga Hosp, Div Urol, Turin, Italy
来源
EUROPEAN UROLOGY FOCUS | 2021年 / 7卷 / 03期
关键词
cT1 renal mass; Upstaging pT3a; Partial nephrectomy; Radical nephrectomy; Predictor upstaging; ROBOTIC PARTIAL NEPHRECTOMY; CELL CARCINOMA; CLINICAL T1; DISEASE; MASSES; RISK;
D O I
10.1016/j.euf.2020.05.013
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Context: Predictors of upstaging from cT1 to pT3a renal masses are poorly inquired, and this remains an area of controversial findings. Objective: To evaluate predictors and outcomes of upstaging from cT1 to pT3a in patients undergoing surgical removal of a renal tumor. Evidence acquisition: A systematic literature search was performed to identify relevant articles using three electronic engines (PubMed, Embase, and Web of Science). Only studies looking at upstaging to pT3a in patients undergoing either partial nephrectomy (PN) or radical nephrectomy (RN) for cT1 renal tumor were included. Study selection was performed according to the Preferred Reporting Items for Systematic Review and Meta analysis (PRISMA) statement. Evidence synthesis: Thirteen studies, including 21869 patients (cT1/pT3a: 1256 [5.7%]; cT1/pT1: 20613 [93.3%]), were identified. Patients in the upstaged group were older (weighted mean difference [WMD]: 3.89; p < 0.00001) and mostly male (odds ratio [OR]: 1.23; p = 0.04). Renal tumors were larger (WMD: 0.98; p < 0.00001), more complex (OR: 2.38; p < 0.0001), and with a higher rate of cT1b masses (OR: 3.36; p < 0.00001). The cT1/pT3a group had a higher rate of other renal cell carcinoma histological subtypes (OR: 1.59; p = 0.04), as well as higher odds of Fuhrman grade >3 (OR: 2.57; p < 0.00001) and positive surgical margins (OR: 1.85; p = 0.007). Five-year recurrence-free survival (RFS) was worse in the upstaged group (OR: 0.31; p = 0.02). Age (OR: 1.03; p < 0.00001), tumor size (OR: 1.51; p < 0.00001), and RENAL score (OR: 2.80; p = 0.0004) were predictors of upstaging. Upstaging was associated with overall survival (hazard ratio [HR]: 1.94; p = 0.05), cancer-specific survival (HR: 2.24; p = 0.007), and RFS (HR: 2.17; p < 0.00001). Conclusions: Upstaging to pT3a in case of surgical removal of a cT1 renal tumor is an uncommon event, which however can translate into worse oncological outcomes. Both patient (older age) and tumor (larger size and higher complexity) characteristics are associated with a higher risk of upstaging. There is very limited evidence regarding whether RN would be better than PN in these cases. There remains an unmet need for tools to better characterize renal masses in the preoperative setting. Patients summary: About 6% of surgically treated localized renal tumors can be found to be locally advanced on final pathology after surgery. This "upstaging" can translate into worse oncological outcomes. There are patient and tumor characteristics that are associated with an increased the risk of upstaging. (c) 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:574 / 581
页数:8
相关论文
共 50 条
  • [1] PERIOPERATIVE MORBIDITY, ONCOLOGICAL OUTCOMES AND PREDICTORS OF PT3A UPSTAGING FOR PATIENTS UNDERGOING PARTIAL NEPHRECTOMY FOR CT1 TUMORS
    Mouracade, Pascal
    Kara, Onder
    Dagenais, Julien
    Maurice, Matthew
    Nelson, Ryan
    Malkoc, Ercan
    Chavali, Jaya Sai
    Kaouk, Jihad
    JOURNAL OF UROLOGY, 2017, 197 (04): : E256 - E256
  • [2] Perioperative morbidity, oncological outcomes and predictors of pT3a upstaging for patients undergoing partial nephrectomy for cT1 tumors
    Pascal Mouracade
    Onder Kara
    Julien Dagenais
    M. J. Maurice
    R. J. Nelson
    Ercan Malkoc
    J. H. Kaouk
    World Journal of Urology, 2017, 35 : 1425 - 1433
  • [3] Perioperative morbidity, oncological outcomes and predictors of pT3a upstaging for patients undergoing partial nephrectomy for cT1 tumors
    Mouracade, Pascal
    Kara, Onder
    Dagenais, Julien
    Maurice, M. J.
    Nelson, R. J.
    Malkoc, Ercan
    Kaouk, J. H.
    WORLD JOURNAL OF UROLOGY, 2017, 35 (09) : 1425 - 1433
  • [4] RECURRENCE IN PATHOLOGIC UPSTAGING TO PT3A IN CT1 RENAL TUMORS
    Karthikeyan, Vilvapathy Senguttuvan
    Mallya, Ashwin
    Sivaraman, Arjun
    Sanchez-Salas, Rafael
    Galiano, Marc
    Rozet, Francois
    Barret, Eric
    Cathelineau, Xavier
    JOURNAL OF UROLOGY, 2016, 195 (04): : E978 - E978
  • [5] Comparison of oncologic outcomes between partial nephrectomy and radical nephrectomy in patients who were upstaged from cT1 renal tumor to pT3a renal cell carcinoma: an updated systematic review and meta-analysis
    Chung, Doo Yong
    Kang, Dong Hyuk
    Kim, Jong Won
    Kim, Do Kyung
    Lee, Joo Yong
    Cho, Kang Su
    THERAPEUTIC ADVANCES IN UROLOGY, 2020, 12
  • [6] CLINICAL IMPORTANCE AND PREDICTIVE FACTORS FOR PT3A UPSTAGING IN CT1 RENAL CELL CARCINOMA
    de Marinho, Ana Catarina
    Simoes, Pedro
    Figueiredo, Arnaldo
    JOURNAL OF UROLOGY, 2021, 206 : E1087 - E1087
  • [7] Oncological outcomes and pathological characteristics of cT1 upstaging to pT3a renal cell carcinoma compared with de novo pT3a tumors
    Karthikeyan, V. Senguttuvan
    Mallya, A.
    Sivaraman, A.
    Galiano, M.
    Rozet, F.
    Cathala, N.
    Barret, E.
    Mombet, A.
    Prapotnich, D.
    Sanchez-Salas, R.
    Cathelineau, X.
    ACTAS UROLOGICAS ESPANOLAS, 2019, 43 (05): : 234 - 240
  • [8] Upstaging to pT3a disease in patients undergoing robotic partial nephrectomy for cT1 kidney cancer: Outcomes and predictors from a multi-institutional dataset
    Veccia, Alessandro
    Antonelli, Alessandro
    Minervini, Andrea
    Mottrie, Alexandre
    Dell'Oglio, Paolo
    Ashrafi, Akbar N.
    Larcher, Alessandro
    Eun, Daniel
    Bradshaw, Aaron
    Amparore, Daniele
    Brassetti, Aldo
    Hampton, Lance J.
    Simeone, Claudio
    Mari, Andrea
    Carini, Marco
    De Naeyer, Geert
    Yang, Kevin
    Capitanio, Umberto
    Simone, Giuseppe
    Porpiglia, Francesco
    Derweesh, Ithaar
    Aron, Monish
    Autorino, Riccardo
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (04) : 286 - 292
  • [9] A meta-analysis for comparison of partial nephrectomy vs. radical nephrectomy in patients with pT3a renal cell carcinoma
    Liu, Hui
    Kong, Qing-Fang
    Li, Jian
    Wu, Yu-Qing
    Pan, Ke-Hao
    Xu, Bin
    Wang, Ya-Li
    Chen, Ming
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2021, 10 (03) : 1170 - 1178
  • [10] Renal functional and cardiovascular outcomes of partial nephrectomy versus radical nephrectomy for renal tumors: a systematic review and meta-analysis
    Ochoa-Arvizo, Mario
    Garcia-Campa, Mariano
    Santos-Santillana, Karla M.
    Klatte, Tobias
    Garcia-Chairez, Luis R.
    Gonzalez-Colmenero, Alejandro D.
    Pallares-Mendez, Rigoberto
    Cervantes-Miranda, Daniel E.
    Plata-Huerta, Hiram H.
    Rodriguez-Gutierrez, Rene
    Gutierrez-Gonzalez, Adrian
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (03) : 113 - 124